| INTRODUCTION
The presence of EGFR-activating mutations in patients with NSCLC can result in increased malignant cell survival, proliferation, invasion, metastatic spread, and tumor angiogenesis. 1, 2 These mutations are estimated to be present in approximately 50% of patients with NSCLC in East Asian countries. 3 Exon 19 deletions and exon 21
L858R substitutions are the most common EGFR mutations. 1, 4 These mutations confer sensitivity to TKIs and account for approximately 90% of EGFR mutations in patients with NSCLC. 5 Patients with NSCLC with EGFR-activating mutations have experienced antitumor activity and prolonged PFS following treatment with the reversible EGFR TKIs such as gefitinib and erlotinib. 6, 7 However, this clinical efficacy is often limited by an acquired drug resistance, most commonly caused by a point mutation (T790M) in the gene encoding EGFR. Approximately 50%-60% of patients treated with TKIs develop T790M-mediated resistance, suggesting that, along with activating mutations, the T790M mutation is an important factor in determining the appropriate treatment strategy in these patients. 8, 9 ASP8273 is an oral, irreversible EGFR TKI that inhibits the kinase activity of EGFR containing the ex19del-or L858R-activating mutation and the T790M resistance mutation with higher potency than WT EGFR. Based on preclinical activity, ASP8273 was evaluated in a phase I/II study in patients with EGFR-mutant lung cancer in Japan.
The primary objectives for phase I of this study were to assess safety/tolerability of ASP8273 as well as to determine the MTD and/or the RP2D based on the DLT profile. Secondary objectives were to determine the pharmacokinetics and antitumor activity of ASP8273. In phase II, the primary objective was to determine the antitumor activity of ASP8273; secondary objectives were to determine the safety and pharmacokinetics of ASP8273. Here, we report the results from study initiation date, January 2014, until the cut-off date, 15 January 2016.
| MATERIALS AND METHODS

| Study design and treatment
This dose-escalation/dose-expansion study (NCT02192697) was undertaken in two phases. Phase I, consisting of a dose-escalation cohort, an additional T790M cohort, and a re-enrollment cohort, was undertaken in four centers in Japan and phase II was held in 15 centers across Japan, Taiwan, and Korea ( Figure 1 ). Eligible patients with NSCLC were aged ≥20 years, had given written informed consent, had an ECOG performance status ≤1, had a histologically or cytologically confirmed diagnosis of NSCLC, were confirmed to have the ex19del, L858R, G719X, or L861Q mutation among the EGFR-activating mutations, and had a life expectancy ≥12 weeks based on investigator's judgment. Eligible patients also met all of the following requirements for laboratory tests within 7 days before enrollment: neutrophil count ≥1500/mm 3 , platelet count ≥75 000/mm 3 , hemoglobin ≥9 g/dL, serum creatinine <1.5 mg/dL, total bilirubin <1.5× the upper limit of normal (this did not apply to patients with Gilbert's syndrome), and AST and ALT <2.5× the upper limit of normal. During phase I, patients received escalating ASP8273 doses (25-600 mg). At least three patients were enrolled at each dose level, depending on the occurrence of DLTs in cycles 0 and 1. Patients enrolled at one dose level were not enrolled at other dose levels.
ASP8273 was given at an initial dose of 25 mg, and then escalated to higher dose levels set at 50, 100, 200, 400, and 600 mg. Among these dose levels, the next recommended dose level was selected according to the posterior mean of DLT rate estimated by the Bayesian continual 
| Study end-points and assessments
A primary end-point of phase I was to determine the safety and tolera- 3 | RESULTS
| Disposition, demographics, and disease characteristics of the overall study
In phase I of this study, 49 patients provided informed consent to participate in the clinical study ( Figure 2 ). A total of 47 patients were enrolled and received the study drug; 45 patients were included in safety and efficacy analyses. The majority of patients were women (n = 33; 73%), all were clinical stage IV, and the majority of patients never smoked (n = 33; 73%). The EGFR ex19del (n = 30; 67%) and L858R (n = 14; 31%) activating mutations were common in this population; 23 patients (51%) harbored a T790M resistance mutation, with the T790M mutation status unknown for 16 patients ( Table 1 ).
The median duration of exposure was 170 days overall and the mean compliance rate was 92%.
Of the 147 patients who provided informed consent to participate in phase II of this study (carried out in Japan, Korea, and Taiwan), 76 were enrolled and received the study drug; all 76 patients were included in the safety analysis set and full analysis set. Similar to phase I, more women (n = 48; 63%) than men (n = 28; 37%) were enrolled, the majority of patients never smoked (n = 51; 67%), and were clinical stage IV (n = 68; 90%). All patients (n = 76) had an EGFR T790M resistance mutation, 52 (68%) had an ex19del-activating mutation, and 22 (29%) had an L858R EGFR-activating mutation.
For this cohort, the median duration of study drug exposure was 196 days and the mean compliance rate was 94%. Across the wide ASP8273 dose-escalation range (25-600 mg), TEAEs occurring in ≥20% of all patients were diarrhea (76%; n = 34), nausea (53%; n = 24), vomiting (49%; n = 22), increased ALT (47%; n = 21), decreased appetite and peripheral sensory neuropathy (38%; n = 17 each), increased AST (36%; n = 16), increased blood creatinine and constipation (33%; n = 15 each), hyponatremia and platelet count decreased (31%; n = 14 each), hypoalbuminemia (22%; n = 10), and F I G U R E 2 Study disposition involving patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor-activating and T790M mutations treated with ASP8273. Phase I, dose escalation; phase II, dose expansion anemia, dry skin, dysgeusia, and malaise (20%; n = 9 each). No deaths were reported during phase I. Serious TEAEs reported in phase I were dehydration, hyponatremia, and diarrhea (4%; n = 2 each).
As detailed in Table 2 , diarrhea (76%; n = 34), vomiting and increased ALT (44%; n = 20), nausea (42%; n = 19), peripheral sensory neuropathy (36%; n = 16), increased AST, increased blood creatinine, and decreased platelet count (31%; n = 14 each) were the most commonly reported TRAEs in phase I. Most of the TRAEs were grade ≤2 in severity; the grade ≥3 TRAEs occurring in ≥2 patients were hyponatremia (20%; n = 9), diarrhea (18%; n = 8), increased AST and anemia (7%; n = 3 each), and colitis, hypoalbuminemia, nausea, and peripheral sensory neuropathy (4%; n = 2 each).
Dose-limiting toxicities were experienced by 9 patients during the study; specifically, 5 patients in the 400 mg dose group and 4
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patients in the 600 mg dose group. All DLTs were of grade ≥3 nonhematologic toxicity, and the most common DLTs were diarrhea (7%; n = 3), followed by colitis, nausea (4%; n = 2 each), and malaise, biliary tract infection, and hyponatremia (2%; n = 1 each). Based on the Bayesian continual reassessment method, the 400 mg dose was recommended as the MTD.
| Pharmacokinetics of ASP8273
ASP8273 showed linear pharmacokinetics and dose proportionality over the dose range of 100 to 400 mg in phase I (Figure 3 ; Tables   S1-S5 
| Phase I antitumor activity
Across the dose range (25-600 mg), the ORR was 49% (95% CI, 33.7,
64.2). Although no patient achieved a CR, 22 patients achieved PR;
additionally, 18 patients achieved SD and five had PD (Table 3) . Disease control rate, defined as CR + PR + SD, was high (89%; n = 40) and the median duration of PFS was 5.6 months (95% CI: 3.6, 11.1).
The duration of response, as assessed by local review, was 8. When antitumor activity was assessed by T790M status, ORRs and DCRs with ASP8273 (25-600 mg) were higher in patients with a known T790M mutation than patients with no T790M mutation (Table 4) . Patients with unknown T790M status had response rates that were similar to patients with known T790M. However, due to the small number of patients in these subgroups, these data should be interpreted with caution.
Based on these efficacy data and a comprehensive evaluation of safety, including the DLT profile and pharmacokinetic data, the RP2D was determined to be 300 mg. TRAEs of special interest
ALT, alanine transaminase; AST, aspartate aminotransferase.
The ORR at week 24, which was assessed at an independent central site, for the phase II population (N = 76) treated with ASP8273 300 mg, was 42% (n = 32; 95% CI, 30.9, 54.0). A total of 32 patients achieved PR, 29 achieved SD, and 8 had PD (Table 5 ).
Disease control rate was 80% and the median duration of PFS by central review was 8.1 months (95% CI, 5.6, upper bound not reached). The proportion of evaluable patients with maximum shrinkage from baseline in the target lesion ≥30%, which was centrally assessed, was 67% (n = 46). As seen in Figure 5 , almost all patients had shrinkage in target lesions. Based on central-tissue testing, the ORR and median duration of PFS were also estimated by the presence or absence of EGFR subtypes ex19del and L8585R, and small differences were observed (Table 6 ).
| Safety and tolerability of ASP8273 300 mg
At the 300 mg dose, TEAEs occurring in ≥20% of patients were diarrhea (66%; n = 50), nausea (41%; n = 31), increased ALT (36%; n = 27), vomiting and decreased appetite (34%; n = 26 each), hyponatremia (33%; n = 25), constipation (26%; n = 20), peripheral sensory neuropathy (25%; n = 19), and increased AST (24%; n = 18). 21% of patients (16/76); the most common (≥2 patients) were hyponatremia (7%; n = 5/76), increased ALT, and decreased appetite (3%; n = 2/76 each). Treatment-emergent AEs leading to permanent discontinuation were reported by 6/76 patients; these were infectious pleural effusion, pneumonia, pyelonephritis, sepsis, hyponatremia, metastases to meninges, and organizing pneumonia.
In phase II, TRAEs were reported by 93% of patients (n = 71);
the most frequently reported were diarrhea (57%; n = 43), hyponatremia and increased ALT (29%; n = 22 each), and vomiting (28%; n = 21). Most TRAEs were mild in severity, however, 15 reports of hyponatremia were grade ≥3 (Table 7) . Tumor imaging data suggested that responses occurred in patients in all dose groups above 100 mg; additionally, when antitumor activity was assessed by T790M status, ORRs, PFS, and DCRs with ASP8273 (25-600 mg) were higher in patients with a known T790M mutation than patients with no T790M mutation. However, due to the small number of patients in these subgroups, these data should be interpreted with caution. In summary, the phase I portion of this study identified the RP2D and MTD of ASP8273 as 300 and 400 mg, respectively, when given orally to patients with clinical stage IV NSCLC. Additionally, we observed during phase II that ASP8273 has a manageable toxicity profile and patients achieved a response rate (CR + PR) of 43%, suggesting ASP8273 has potential antitumor effects.
| DISCUSSION
